

*Place:* NIH, Rockledge 2, Room 5170, Telephone Conference.

*Contact Person:* Dr. Luigi Giacometti, Scientific Review Administrator, 6701 Rockledge Drive, Room 5170, Bethesda, Maryland 20892, (301) 435-1246.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* December 2, 1996.

*Time:* 3:30 p.m.

*Place:* NIH, Rockledge 2, Room 5196, Telephone Conference.

*Contact Person:* Ms. Carol Campbell, Scientific Review Administrator, 6701 Rockledge Drive, Room 5196, Bethesda, Maryland 20892, (301) 435-1257.

*Name of SEP:* Clinical Sciences.

*Date:* December 2, 1996.

*Time:* 5:00 p.m.

*Place:* NIH, Rockledge 2, Room 4104, Telephone Conference.

*Contact Person:* Dr. Priscilla Chen, Scientific Review Administrator, 6701 Rockledge Drive, Room 4104, Bethesda, Maryland 20892, (301) 435-1787.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* December 4, 1996.

*Time:* 11:00 a.m.

*Place:* NIH, Rockledge 2, Room 5126, Telephone Conference.

*Contact Person:* Dr. Anne Clark, Scientific Review Administrator, 6701 Rockledge Drive, Room 5126, Bethesda, Maryland 20892, (301) 435-1017.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* December 4, 1996.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge 2, Room 4178, Telephone Conference.

*Contact Person:* Dr. Jean Hickman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4178, Bethesda, Maryland 20892, (301) 435-1146.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* December 6, 1996.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge 2, Room 4178, Telephone Conference.

*Contact Person:* Dr. Jean Hickman, Scientific Review Administrator, 6701 Rockledge Drive, Room 4178, Bethesda, Maryland 2892, (301) 435-1146.

*Name of SEP:* Clinical Sciences.

*Date:* December 9, 1996.

*Time:* 9:00 a.m.

*Place:* NIH, Rockledge 2, Room 4104, Telephone Conference.

*Contact Person:* Dr. Priscilla Chen, Scientific Review Administrator, 6701 Rockledge Drive, Room 4104, Bethesda, Maryland 20892, (301) 435-1787.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* December 9-11, 1996.

*Time:* 4:00 p.m.

*Place:* Stratford Inn, Del Mar, California.

*Contact Person:* Dr. Nancy Lamontagne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4170, Bethesda, Maryland 20892, (301) 435-1726.

*Name of SEP:* Behavioral and Neurosciences.

*Date:* December 13, 1996.

*Time:* 2:00 p.m.

*Place:* NIH, Rockledge 2, Room 5172, Telephone Conference.

*Contact Person:* Dr. Leonard Jakubczak, Scientific Review Administrator, 6701 Rockledge Drive, Room 5172, Bethesda, Maryland 20892, (301) 435-1247.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

*Dated:* November 6, 1996.

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 96-29253 Filed 11-14-96; 8:45 am]

**BILLING CODE 4140-01-M**

### **Division of Research Grants; Notice of Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* December 9, 1996.

*Time:* 12:00 p.m.

*Place:* NIH, Rockledge 2, Room 4142, Telephone Conference.

*Contact Person:* Dr. Edmund Copeland, Scientific Review Administrator, 6701 Rockledge Drive, Room 4142, Bethesda, Maryland 20892, (301) 435-1715.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* December 10, 1996.

*Time:* 10:00 a.m.

*Place:* NIH, Rockledge 2, Room 5208, Telephone Conference.

*Contact Person:* Dr. Houston Baker, Scientific Review Administrator, 6701 Rockledge Drive, Room 5208, Bethesda, Maryland 20892, (301) 435-1175.

*Name of SEP:* Clinical Sciences.

*Date:* December 12, 1996.

*Time:* 2:00 p.m.

*Place:* NIH, Rockledge 2, Room 4100, Telephone Conference.

*Contact Person:* Dr. Jeanne Ketley, Scientific Review Administrator, 6701 Rockledge Drive, Room 4100, Bethesda, Maryland 20892, (301) 435-1789.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* December 15, 1996.

*Time:* 6:00 p.m.

*Place:* Hyde Park Ramada Inn, Chicago, IL.

*Contact Person:* Dr. Houston Baker, Scientific Review Administrator, 6701 Rockledge Drive, Room 5208, Bethesda, Maryland 20892, (301) 435-1175.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* December 15-16, 1996.

*Time:* 7:00 p.m.

*Place:* Hyde Park Ramada Inn, Chicago, IL.

*Contact Person:* Dr. Houston Baker, Scientific Review Administrator, 6701 Rockledge Drive, Room 5208, Bethesda, Maryland 20892, (301) 435-1175.

*Name of SEP:* Clinical Sciences.

*Date:* December 16, 1996.

*Time:* 2:00 p.m.

*Place:* NIH, Rockledge 2, Room 4100, Telephone Conference.

*Contact Person:* Dr. Jeanne Ketley, Scientific Review Administrator, 6701 Rockledge Drive, Room 4100, Bethesda, Maryland 20892, (301) 435-1789.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* December 19, 1996.

*Time:* 2:00 p.m.

*Place:* NIH, Rockledge 2, Room 5150, Telephone Conference.

*Contact Person:* Dr. Zakir Bengali, Scientific Review Administrator, 6701 Rockledge Drive, Room 5150, Bethesda, Maryland 20892, (301) 435-1742.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Paula N. Hayes,

*Acting Committee Management Officer, NIH.*

[FR Doc. 96-29342 Filed 11-14-96; 8:45 am]

**BILLING CODE 4140-01-M**

### **Prospective Grant of a Partially Exclusive License: Pseudomonas-Exotoxin-Based Fusion Protein Cancer Therapy**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a partially exclusive license in the United States and abroad to practice the inventions embodied in U.S. Patent Application Serial No. 08/077,252, entitled "Recombinant

Disulfide-Stabilized Polypeptide Fragments Having Binding Specificity"; U.S. Patent Application Serial Nos. 08/405,615, 08/463,480, and 08/461,234, all entitled "Recombinant Pseudomonas Exotoxin with Increased Activity," and U.S. Patent Application No. 08/331,398, entitled "Single-Chain B3 Antibody Fusion Proteins and Their Uses" to The Therapeutics Division of Boehringer-Mannheim Corporation having a place of business in Rockville, MD. The patent rights in these inventions have been assigned to the United States of America.

**SUPPLEMENTARY INFORMATION:** The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR § 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR § 404.7.

The field of use would be limited to Pseudomonas-Exotoxin-based fusion protein cancer therapy.

The present invention relates to modifications of recombinant Pseudomonas exotoxin with insertion of various targeting molecules specific for a given target site. The modified exotoxin of this invention may prove to be a valuable cancer therapeutic when fused to various target-specific cell recognition proteins. The modifications result in reduced non-specific cytotoxicity while increasing target specific cytotoxicity.

**ADDRESSES:** Requests for a copy of the subject issued patent, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Larry M. Tiffany, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 206; Facsimile: (301) 402-0220.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before January 14, 1997 will be considered. Comments and objections will not be made available for public inspection and, to the extent permitted by law, will not be subject to disclosure under the Freedom of Information Act, 5 U.S.C. 552.

Dated: November 4, 1996.  
Barbara M. McGarey,  
*Deputy Director, Office of Technology Transfer.*  
[FR Doc. 96-29255 Filed 11-14-96; 8:45 am]  
**BILLING CODE 4140-01-M**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4124-N-12]

### Federal Property Suitable as Facilities To Assist the Homeless

**AGENCY:** Office of the Assistant Secretary for Community Planning and Development, HUD.

**ACTION:** Notice.

**SUMMARY:** This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

**FOR FURTHER INFORMATION CONTACT:** Mark Johnston, room 7256, Department of Housing and Urban Development, 451 Seventh Street SW., Washington, DC 20410; telephone (202) 708-1226; TDD number for the hearing- and speech-impaired (202) 708-2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.

**SUPPLEMENTARY INFORMATION:** In accordance with 24 CFR Part 581 and section 501 of the Stewart B. McKinney Homeless Assistance Act (42 U.S.C. 11411), as amended, HUD is publishing this Notice to identify Federal buildings and other real property that HUD has reviewed for suitability for use to assist the homeless. The properties were reviewed using information provided to HUD by Federal landholding agencies regarding unutilized and underutilized buildings and real property controlled by such agencies or by GSA regarding its inventory of excess or surplus Federal property. This Notice is also published in order to comply with the December 12, 1988 Court Order in *National Coalition for the Homeless v. Veterans Administration*, No. 88-2503-OG (D.D.C.).

Properties reviewed are listed in this Notice according to the following categories: Suitable/available, suitable/unavailable, suitable/to be excess, and unsuitable. The properties listed in the three suitable categories have been reviewed by the landholding agencies, and each agency has transmitted to HUD: (1) Its intention to make the property available for use to assist the homeless, (2) its intention to declare the property excess to the agency's needs, or

(3) a statement of the reasons that the property cannot be declared excess or made available for use as facilities to assist the homeless.

Properties listed as suitable/available will be available exclusively for homeless use for a period of 60 days from the date of this Notice. Homeless assistance providers interested in any such property should send a written expression of interest to HHS, addressed to Brian Rooney, Division of Property Management, Program Support Center, HHS, room 5B-41, 5600 Fishers Lane, Rockville, MD 20857; (301) 443-2265. (This is not a toll-free number.) HHS will mail to the interested provider an application packet, which will include instructions for completing the application. In order to maximize the opportunity to utilize a suitable property, providers should submit their written expressions of interest as soon as possible. For complete details concerning the processing of applications, the reader is encouraged to refer to the interim rule governing this program, 24 CFR Part 581.

For properties listed as suitable/to be excess, that property may, if subsequently accepted as excess by GSA, be made available for use by the homeless in accordance with applicable law, subject to screening for other Federal use. At the appropriate time, HUD, will publish the property in a Notice showing it as either suitable/available or suitable/unavailable.

For properties listed as suitable/unavailable, the landholding agency has decided that the property cannot be declared excess or made available for use to assist the homeless, and the property will not be available.

Properties listed as unsuitable will not be made available for any other purpose for 20 days from the date of this Notice. Homeless assistance providers interested in a review by HUD of the determination of unsuitability should call the toll free information line at 1-800-927-7588 for detailed instructions or write a letter to Mark Johnston at the address listed at the beginning of this Notice. Included in the request for review should be the property address (including zip code), the date of publication in the Federal Register, the landholding agency, and the property number.

For more information regarding particular properties identified in this Notice (*i.e.*, acreage, floor plan, existing sanitary facilities, exact street address), providers should contact the appropriate landholding agencies at the following addresses: Air Force: Ms. Barbara Jenkins, Air Force Real Estate Agency, (Area-MI), Bolling Air Force